Patriot Financial Group Insurance Agency LLC Buys 296 Shares of Bio-Rad Laboratories, Inc. $BIO

Patriot Financial Group Insurance Agency LLC lifted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 25.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,441 shares of the medical research company’s stock after purchasing an additional 296 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Bio-Rad Laboratories were worth $348,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BIO. Quarry LP bought a new position in Bio-Rad Laboratories in the 1st quarter valued at approximately $29,000. Curat Global LLC bought a new position in Bio-Rad Laboratories in the 1st quarter valued at approximately $34,000. Allworth Financial LP lifted its position in Bio-Rad Laboratories by 260.0% in the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 104 shares in the last quarter. UMB Bank n.a. lifted its position in Bio-Rad Laboratories by 89.8% in the 2nd quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 79 shares in the last quarter. Finally, Headlands Technologies LLC lifted its position in Bio-Rad Laboratories by 64.1% in the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock valued at $87,000 after acquiring an additional 139 shares in the last quarter. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Stock Up 3.8%

Shares of NYSE:BIO opened at $305.47 on Friday. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $387.99. The company has a 50-day moving average price of $281.55 and a 200 day moving average price of $254.73. The company has a market cap of $8.27 billion, a price-to-earnings ratio of 26.04 and a beta of 0.97.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The firm had revenue of $651.60 million during the quarter, compared to the consensus estimate of $614.82 million. During the same quarter last year, the firm earned $3.11 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BIO has been the topic of several analyst reports. Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 22nd. Wells Fargo & Company upped their price objective on Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Weiss Ratings reiterated a “sell (d)” rating on shares of Bio-Rad Laboratories in a research note on Saturday, September 27th. Finally, Royal Bank Of Canada increased their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Bio-Rad Laboratories has an average rating of “Hold” and a consensus target price of $333.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.